Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

May 3, 2022

Alon Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics, which is working on ALS therapy and other neurodegenerative diseases like Parkinson's and Alzheimer's. They are working on a disease-modifying drug PrimeC and have identified a large set of biomarkers that are related to ALS progression and the mechanisms of PrimeC.

Alon explains, "Our lead candidate is called PrimeC. It's a novel formulation that consists of two FDA-approved drugs not related to ALS. We found that when these drugs are combined together in unique doses, they had the quality to treat ALS and tackle ALS in several forms. This formulation aims to maximize the synergism that we found to have between these compounds and as I mentioned, to tackle multiple targets in order to eventually create a clinical benefit for the patients."

"We are advancing with identifying biomarkers and progressing there very nicely. We identified a large set of biomarkers that relates both to the disease progression and to the mechanisms of PrimeC. We work on neuron-derived exosomes, and when we first characterize the set of biomarkers that are relevant for us, we also explored how PrimeC, our lead candidate, can create a change in these biomarkers."

@NeuroSenseT #NeuroSense #Neurodegenerative #PrimeC #Biotech #RareDiseases #CNS #ALS #Alzheirmers #AD #Parkinsons #PD #Biomarkers

Download the transcript here